These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 28233269

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 5. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N, Paragh G, Harangi M.
    Orv Hetil; 2014 Apr 20; 155(16):607-14. PubMed ID: 24733102
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov 20; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 9. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E.
    Atheroscler Suppl; 2015 May 20; 18():263-7. PubMed ID: 25936335
    [Abstract] [Full Text] [Related]

  • 10. Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?
    Mellwig KP, Horstkotte D, van Buuren F.
    Clin Res Cardiol Suppl; 2017 Mar 20; 12(Suppl 1):18-21. PubMed ID: 28233270
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar 20; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S, Fischer S, Weiss N, Julius U.
    Atheroscler Suppl; 2015 May 20; 18():209-14. PubMed ID: 25936328
    [Abstract] [Full Text] [Related]

  • 17. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
    Heigl F, Hettich R, Mauch E, Klingel R, Fassbender C.
    Clin Res Cardiol Suppl; 2017 Mar 20; 12(Suppl 1):50-54. PubMed ID: 28160245
    [Abstract] [Full Text] [Related]

  • 18. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 20; 18():215-25. PubMed ID: 25936329
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.